**Notice of Intent to Certify Sole Source**

**To:** Interested Parties

**From: Ellen Swoger**

CIO, Applications

**Date:** 12/8/2023

**Re:** Sole Source Certification Number **SS9618** for Software for Ingenuity Pathway Analysis

**Contact Email Address:** [solesource@umc.edu](mailto:solesource@umc.edu)

**Sole Source Certification Award Details**

Regarding UMMC Sole Source Certification Number 9618 for Software for Ingenuity Pathway Analysis, please be advised that UMMC intends to award the purchase of the Software for Ingenuity Pathway Analysis (IPA), IPA®, to QIAGEN N.V. QIAGEN N.V. is the sole developer, provider and source of Ingenuity Pathway Analysis (IPA**®**) software.

UMMC issues this notice in accordance with Mississippi state law, policy, and procedures for sole source procurements.

Sole Source Criteria

1. Where the compatibility of equipment, accessories, or replacement parts is the paramount consideration (and manufacturer is the sole supplier).
2. Where a sole supplier’s item is needed for trial use or testing.
3. Where a sole supplier’s item is to be required when no other item will service the needs of UMMC.

**Schedule**

|  |  |
| --- | --- |
| **Task** | **Date** |
| First Advertisement Date | December 14, 2023 |
| Second Advertisement Date | December 21, 2023 |
| Response Deadline from Objectors | December 29, 2023, at 3:00 p.m. Central Time |
| Notice of Award/No Award Posted | Not before December 29, 2023 |

**Project Details**

1. **Describe the commodity/service that the agency/institution is seeking to procure:**

Ingenuity Pathway Analysis IPA® is an all-in-one, web-based software application that enables researchers to analyze, integrate, and understand data derived from gene expression, microRNA, and SNP microarrays; phosphoproteomics, metabolomics, proteomics, and RNA-Seq experiments; and small-scale experiments that generate gene and chemical lists. Ingenuity Pathway Analysis (IPA) allows researchers to input gene and/or protein direction regulation allowing to simultaneously asses the effect of genes and microRNAs up- and down-regulated. With IPA, researchers can search for targeted information on genes, proteins, chemicals, and drugs, and build interactive models of our experimental systems. IPA’s data analysis and search capabilities help researchers understand the significance of data, specific target, or candidate biomarker in the context of larger biological or chemical systems, backed by the Ingenuity® Knowledge Base of highly structured, detail-rich biological and chemical Findings.

1. **Explain why the commodity/service is the only one (1) that can meet the needs of the agency/institution:**

The IPA® Ingenuity® Knowledge Base is distinctive because of the breadth of biological and chemical knowledge, accuracy and structure of the content for relationship and computation using the Ingenuity Ontology.IPA has been adopted by all major pharmaceutical companies and hundreds of leading biotech, academic, and government institutions. Ingenuity Pathway Analysis (IPA) is the "gold standard" in the field due to a dedicated large set of scientists that continuously search, curate and input information from multiple sources into the master IPA® database.

1. **Explain why the source is the only person or entity that can provide the required commodity/service:**

QIAGEN N.V. is the sole developer, provider and source of Ingenuity Pathway Analysis (IPA**®**) software. See supporting letter from QIAGEN N.V., Attachment A.

1. **Explain why the amount to be expended for the commodity/service is reasonable:**

The estimated amount to be expended for the purchase of the Ingenuity Pathway Analysis (IPA**®**) software is $**18,133.05** for three years. Please be advised that UMMC will determine if additional enhancements, upgrades, support, or equipment are within scope during the certification period and may increase the spending authority accordingly. Should QIAGEN N.V. change their name during this certification period, then UMMC will determine if a recertification is necessary. This amount is within the expected price range for these products.

1. **Describe the efforts that the agency/institution went through to obtain the best possible price for the commodity/service:**

Pricing is compared against available market intelligence and identified discounts are pursued where applicable.

**Submission Instructions and Format of Response from Objecting Parties**

Interested parties who have reason to believe that Ingenuity Pathway Analysis (IPA**®**) software (hereafter, “Products”) should not be certified as a sole source should provide information in the Vendor Form for the State to use in determining whether or not to proceed with awarding the sole source to QIAGEN N.V. The Vendor Form may be found at <http://www.dfa.state.ms.us/Purchasing/documents/ObjectiontoSoleSourceDetermination.pdf>.

Objections must include the certification in Attachment B.

Comments will be accepted at any time prior to Friday, December 29, 2023, at 3:00 p.m. (Central Time) to [solesource@umc.edu](mailto:solesource@umc.edu). Responses may be delivered via email to [solesource@umc.edu](mailto:solesource@umc.edu). UMMC WILL NOT BE RESPONSIBLE FOR DELAYS IN THE DELIVERY OF RESPONSES. It is solely the responsibility of the Interested Parties that responses reach UMMC on time. Responses received after the deadline and responses that lack all required information will be rejected. UMMC reserves the right to inspect Interested Party’s commodity for comparison purposes.

If you have any questions concerning the information above or if we can be of further assistance, please contact [solesource@umc.edu](mailto:solesource@umc.edu).

Attachment A: Vendor Correspondence

Attachment B: Objection Certification

Attachment B

**SUBMITTED IN RESPONSE TO**

**Sole Source Certification No. SS9618**

**Accepted until Friday, December 29, 2023, at 3:00 p.m.**

I certify that the information contained in this objection is true and accurate to the best of my knowledge. I understand that UMMC will investigate all statements made in this objection and that any false or misleading information provided may result in adverse action.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Objector Name

Objector’s title

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Date